Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report

Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report

Upper tract urothelial carcinoma (UTUC) is often diagnosed late and exhibits poor prognosis. Only limited data are available concerning therapeutic regimes and potential biomarkers for disease monitoring. Standard therapies often provide only insufficient treatment options. Hence, immunotherapies an...

Full description

Bibliographic Details
Main Authors: Arnulf Stenzl, Florian Battke, Martin Schulze, Maria Kopp, Maximilian Frick, Saskia Biskup, Carolin Blumendeller, Julius Boehme, Antje Rinckleb, Christina Kyzirakos, Simone Kayser, Sabine Kelkenberg, Natalia Pieper, Oliver Bartsch, Dirk Hadaschick
Format: Article
Language:English
Published: BMJ Publishing Group 2021-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/1/e001406.full

Internet

https://jitc.bmj.com/content/9/1/e001406.full

Similar Items